واکسن اچ‌آی‌وی
کارهای آینده

مطالعات نشان داده‌اند که بیماران مبتلا به HIV که هم‌زمان با ویروس GBV-C (ویروس هپاتیت G) آلوده شده‌اند، نسبت به سایر بیماران HIV طول عمر بیشتری دارند. این موضوع ممکن است در توسعه واکسن HIV در آینده مفید باشد.
واکسن‌های ضعیف‌شده زنده (Live Attenuated Vaccines)
واکسن‌های ضعیف‌شده زنده برای بیماری‌هایی مانند فلج اطفال، روتاویروس و سرخک موفق بوده‌اند، اما تاکنون در برابر HIV آزمایش نشده‌اند. دلیل اصلی نگرانی، خطر بازگشت ویروس به حالت فعال است.
محققان در حال بررسی روش‌های جدید برای توسعه واکسن HIV زنده، اما غیرقابل تکثیر هستند. یکی از این روش‌ها شامل دست‌کاری ژنتیکی HIV است تا پروتئین‌های آن برای تکثیر نیاز به یک اسید آمینه غیرطبیعی داشته باشند که در بدن انسان وجود ندارد، بنابراین ویروس نمی‌تواند تکثیر شود.
↑  Gray GE, Laher F, Lazarus E, Ensoli B, Corey L (آوریل ۲۰۱۶). "Approaches to preventative and therapeutic HIV vaccines". Current Opinion in Virology. 17: 104–109. doi:10.1016/j.coviro.2016.02.010. PMC 5020417. PMID 26985884.
↑  Shilts, Randy (1987). And the Band Played On: Politics, People, and the AIDS Epidemic (2007 ed.). St. Martin's Press. p. 451. ISBN 978-0-312-24135-3.
↑  Fauci AS (1996). "An HIV vaccine: breaking the paradigms". Proc. Am. Assoc. Phys. 108 (1): 6–13. PMID 8834058.
↑  Kim D, Elizaga M, Duerr A (March 2007). "HIV vaccine efficacy trials: towards the future of HIV prevention". Infectious Disease Clinics of North America. 21 (1): 201–17, x. doi:10.1016/j.idc.2007.01.006. PMID 17502236.
↑  Watkins DI (March 2008). "The hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a review". Memórias do Instituto Oswaldo Cruz. 103 (2): 119–29. doi:10.1590/S0074-02762008000200001. PMC 2997999. PMID 18425263.
↑  Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T (October 2007).  Nixon D (ed.). "Design and pre-clinical evaluation of a universal HIV-1 vaccine". PLOS ONE. 2 (10): e984. Bibcode:2007PLoSO...2..984L. doi:10.1371/journal.pone.0000984. PMC 1991584. PMID 17912361.
↑  West AP, Jr; Diskin, R; Nussenzweig, MC; Bjorkman, PJ (24 July 2012). "Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120". Proceedings of the National Academy of Sciences of the United States of America. 109 (30): E2083-90. Bibcode:2012PNAS..109E2083W. doi:10.1073/pnas.1208984109. PMC 3409792. PMID 22745174.
↑  Lee, Jeong Hyun; Toy, Laura; Kos, Justin T.; Safonova, Yana; Schief, William R.; Havenar-Daughton, Colin; Watson, Corey T.; Crotty, Shane (6 September 2021). "Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells". npj Vaccines. 6 (1): 113. doi:10.1038/s41541-021-00376-7. PMC 8421370. PMID 34489473.
↑  "Key HIV Protein Structure Revealed". National Institutes of Health (NIH) (به انگلیسی). 2015-05-14. Retrieved 2023-01-05. This article incorporates text from this source, which is in the public domain.
↑  Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H,  et al. (April 1999). "Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo". Immunity. 10 (4): 431–8. doi:10.1016/S1074-7613(00)80043-6. PMID 10229186.
↑  Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP,  et al. (June 1990). "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160". Nature. 345 (6276): 622–5. Bibcode:1990Natur.345..622B. doi:10.1038/345622a0. PMID 2190095. S2CID 4258128.
↑  Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD,  et al. (February 1998). "Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines". Journal of Virology. 72 (2): 1552–76. doi:10.1128/JVI.72.2.1552-1576.1998. PMC 124637. PMID 9445059.
↑  Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R,  et al. (August 2008). "The use of nonhuman primate models in HIV vaccine development". PLOS Medicine. 5 (8): e173. doi:10.1371/journal.pmed.0050173. PMC 2504486. PMID 18700814.
↑  Marques R, Williams A, Eksmond U, Wullaert A, Killeen N, Pasparakis M,  et al. (2009). "Generalized immune activation as a direct result of activated CD4+ T cell killing". Journal of Biology. 8 (10): 93. doi:10.1186/jbiol194. PMC 2790834. PMID 19943952.
↑  Vrisekoop N, Mandl JN, Germain RN (2009). "Life and death as a T lymphocyte: from immune protection to HIV pathogenesis". Journal of Biology. 8 (10): 91. doi:10.1186/jbiol198. PMC 2790836. PMID 19951397.
↑  Lin, YR; Parks, KR; Weidle, C; Naidu, AS; Khechaduri, A; Riker, AO; Takushi, B; Chun, JH; Borst, AJ; Veesler, D; Stuart, A; Agrawal, P; Gray, M; Pancera, M; Huang, PS; Stamatatos, L (13 October 2020). "HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors". Immunity. 53 (4): 840–851.e6. doi:10.1016/j.immuni.2020.09.007. PMC 7735217. PMID 33053332.
↑  Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW,  et al. (June 2018). "Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial". The Lancet. HIV. 5 (7): e366–e378. doi:10.1016/S2352-3018(18)30071-7. PMC 6028742. PMID 29898870.
↑  Pavot V, Rochereau N, Lawrence P, Girard MP, Genin C, Verrier B, Paul S (July 2014). "Recent progress in HIV vaccines inducing mucosal immune responses". AIDS. 28 (12): 1701–18. doi:10.1097/qad.0000000000000308. PMID 25009956. S2CID 28618851.
↑  "New Vaccine Could Turn HIV Into Minor Infection". Fox News. 2011-09-29. Archived from the original on 2011-09-29. Retrieved 29 September 2011.
↑  Choi E, Michalski CJ, Choo SH, Kim GN, Banasikowska E, Lee S,  et al. (November 2016). "First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses". Retrovirology. 13 (1): 82. doi:10.1186/s12977-016-0317-2. PMC 5126836. PMID 27894306.
↑  "STEP Study Locations". Archived from the original on 2008-07-24. Retrieved 2008-11-04.
↑  Joint United Nations Programme on HIV/AIDS (UNAIDS) (December 2005). "AIDS epidemic update" (PDF). World Health Organization. Archived (PDF) from the original on 2014-06-29. Retrieved 2014-04-22.
↑  Efficacy Results from the STEP Study (Merck V520 Protocol 023/HVTN 502) بایگانی‌شده  در ۲۰۱۱-۰۷-۲۶ توسط Wayback Machine
↑  Sekaly RP (January 2008). "The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?". The Journal of Experimental Medicine. 205 (1): 7–12. doi:10.1084/jem.20072681. PMC 2234358. PMID 18195078.
↑  Iaccino E, Schiavone M, Fiume G, Quinto I, Scala G (July 2008). "The aftermath of the Merck's HIV vaccine trial". Retrovirology. 5: 56. doi:10.1186/1742-4690-5-56. PMC 2483718. PMID 18597681.
↑  Corey, Lawrence; Gilbert, Peter B.; Juraska, Michal; Montefiori, David C.; Morris, Lynn; Karuna, Shelly T.; Edupuganti, Srilatha; Mgodi, Nyaradzo M.; deCamp, Allan C.; Rudnicki, Erika; Huang, Yunda (2021-03-18). "Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition". The New England Journal of Medicine. 384 (11): 1003–1014. doi:10.1056/NEJMoa2031738. ISSN 1533-4406. PMC 8189692. PMID 33730454.
↑  "Candidate for new AIDS vaccine advances to next phase of pre-approval trials". Tech2 (به انگلیسی). 2018-07-08. Retrieved 2018-07-11.
↑  "HIV Vaccine Candidate Does Not Sufficiently Protect Women Against HIV Infection". National Institutes of Health (NIH) (به انگلیسی). 31 August 2021. Retrieved 1 September 2021.
↑  "Investing to End the AIDS Epidemic: A new Era for HIV Prevention Research and Development" (PDF). Archived from the original (PDF) on 2012-12-14. Retrieved 2010-12-13.
↑  Berndt ER, Glennerster R, Kremer M, Lee J, Levine R, Weizsacker G,  et al. (April 2005). "Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness" (PDF). NBER Working Paper. doi:10.2139/ssrn.696741. SSRN 696741. Archived (PDF) from the original on 2013-07-21. Retrieved 2021-12-11.
↑  Collier, Leslie; Balows, Albert; Sussman, Max (1998).  Mahy, Brian; Collier, Leslie (eds.). Virology. Topley and Wilson's Microbiology and Microbial Infections. Vol. 1 (ninth ed.). Hodder Education Publishers. pp. 75–91. ISBN 978-0-340-66316-5.
↑  McGovern SL, Caselli E, Grigorieff N, Shoichet BK (April 2002). "A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening". Journal of Medicinal Chemistry. 45 (8): 1712–22. doi:10.1021/jm010533y. PMID 11931626.
↑  Foley B, Leitner T, Apetrei C, Hahn B, Mizrachi I, Mullins J, Rambaut A, Wolinsky S, Korber B (2017). HIV Sequence Compendium (Report). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, LA-UR 17-25240.
↑  Malashkevich VN, Chan DC, Chutkowski CT, Kim PS (August 1998). "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides". Proceedings of the National Academy of Sciences of the United States of America. 95 (16): 9134–9. doi:10.1073/pnas.95.16.9134. PMC 21304. PMID 9689046.
↑  Bagasra O, Bagasra AU, Sheraz M, Pace DG (March 2012). "Potential utility of GB virus type C as a preventive vaccine for HIV-1". Expert Review of Vaccines. 11 (3): 335–47. doi:10.1586/erv.11.191. PMID 22380825.
↑  Wang N, Li Y, Niu W, Sun M, Cerny R, Li Q, Guo J (May 2014). "Construction of a live-attenuated HIV-1 vaccine through genetic code expansion". Angewandte Chemie. 53 (19): 4867–71. PMID 24715496.
چرخه ساختاری HIV
شامپانزه‌های جوان در پناهگاه چین‌پونگا (جمهوری کنگو)